Rogers
Yahoo Finance • 54 minutes ago
Roche Holding (SWX:ROG) Valuation Check After Recent Share Price Momentum And Conflicting Fair Value Views
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. What recent performance says about Roche Holding shares Roche Holding (SWX:ROG) has drawn fresh attention after a sol... Full story
Yahoo Finance • yesterday
IEFA vs. SPGM: Does This Developed Markets ETF Have the Edge Over A Global ETF?
Key Points IEFA offers higher recent returns and a significantly higher dividend yield than SPGM. SPGM provides broader global exposure including U.S. and emerging markets, while IEFA focuses on developed markets outside North America. 1... Full story
Yahoo Finance • 2 days ago
IEFA vs. IEMG: Comparing the Emerging and Developed Markets
Both the iShares Core MSCI Emerging Markets ETF (NYSEMKT:IEMG) and iShares Core MSCI EAFE ETF (NYSEMKT:IEFA) are designed as core holdings for international diversification, but IEMG targets emerging markets while IEFA invests in developed... Full story
Yahoo Finance • 2 days ago
IEFA vs. NZAC: How Does A Foreign Fund Matchup Against A Sustainable ETF?
Key Points IEFA charges a lower expense ratio and nearly doubles the dividend yield of NZAC's. IEFA’s recent one-year return outpaced NZAC, but both saw similar five-year drawdowns.10 stocks we like better than iShares Trust - iShares Co... Full story
Yahoo Finance • 3 days ago
Genentech’s Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS)
– Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, Ocrevus, in reducing disability progression in PPMS –... Full story
Yahoo Finance • 3 days ago
Roche’s fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)
F. Hoffmann-La Roche Ltd Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, OCREVUS, in reducing disabilit... Full story
Yahoo Finance • last month
Alibaba Group Holding Ltd: A Major Addition to Invesco EQV European Equity Fund's Portfolio
This article first appeared on GuruFocus. Invesco EQV European Equity Fund (Trades, Portfolio)'s Strategic Moves in Q4 2025 Warning! GuruFocus has detected 3 Warning Signs with HKSE:09988. Is HKSE:09988 fairly valued? Test your thesis wi... Full story
Yahoo Finance • 2 months ago
Is FDA’s Fast Subcutaneous Lunsumio VELO Approval Reshaping the Investment Case For Roche (SWX:ROG)?
In December 2025, Genentech, part of the Roche Group, received U.S. FDA accelerated approval for Lunsumio VELO, a subcutaneous formulation of mosunetuzumab for adults with relapsed or refractory follicular lymphoma after at least two prior... Full story
Yahoo Finance • 2 months ago
FDA Approves Genentech’s Lunsumio VELO™ for Subcutaneous Use in Relapsed or Refractory Follicular Lymphoma
– Lunsumio VELO reduces administration time from 2-4 hours to approximately one minute – – Availability of Lunsumio VELO allows treatment aligned to people’s clinical needs and personal preferences – – Approval supported by data demonstr... Full story
Yahoo Finance • 2 months ago
FDA approves Roche’s Lunsumio VELO™ for subcutaneous use in relapsed or refractory follicular lymphoma
F. Hoffmann-La Roche Ltd Lunsumio VELO reduces administration time from 2-4 hours to approximately one minute Availability of Lunsumio VELO allows treatment aligned to people’s clinical needs and personal preferences Approval supported b... Full story
Yahoo Finance • 2 months ago
Does Roche Still Offer Value After a 35.9% Rally and New Oncology Partnerships?
If you are wondering whether Roche Holding is still an attractive opportunity after its recent run, or whether that value is already reflected in the price, this article will walk through what the numbers are really indicating about the st... Full story
Yahoo Finance • 2 months ago
Genentech Announces Agreement With U.S. Government
– Agreement with the U.S. government addresses prescription drug costs and encourages other wealthy nations to reward biopharmaceutical innovation – – Influenza portfolio to be made available through TrumpRx.gov and through Genentech’s re... Full story
Yahoo Finance • 2 months ago
Roche (SWX:ROG) Valuation Check After 25% Year-to-Date Share Price Rally
Roche Holding (SWX:ROG) has been quietly rewarding patient shareholders, with the stock gaining about 12% over the past month and roughly 25% year to date, outpacing many large pharma peers. See our latest analysis for Roche Holding. Tha... Full story
Yahoo Finance • 2 months ago
Roche announces U.S. launch of next-generation cobas 6800/8800 systems and software, enhancing laboratory efficiency and testing capabilities
The new cobas® 6800/8800 Systems version 2.0 and software version 2.0.1 enhances throughput, run flexibility, enables sample prioritization and is available as an upgrade to existing systems. Laboratories can now perform a greater variety... Full story
Yahoo Finance • 2 months ago
Roche receives FDA approval for first diagnostic tests to identify HER2-positive metastatic breast cancer patients eligible for ENHERTU
FDA expands labels for Roche's PATHWAY HER2 (4B5) test* and VENTANA HER2 Dual ISH DNA Probe Cocktail, which can now be used to identify HER2-positive metastatic breast cancer patients that could be eligible for ENHERTU. Roche's PATHWAY HE... Full story
Yahoo Finance • 2 months ago
Roche Secures CE Mark Approval For Automated Mass Spectrometry Reagent Pack
(RTTNews) - Roche (RHHBY, RO.SW, ROG.SW) announced that it has obtained CE Mark approval for its mass spectrometry reagent pack designed for antibiotics drug monitoring. This milestone establishes Roche's in-vitro diagnostics (IVD) menu as... Full story
Yahoo Finance • 2 months ago
Roche expands automated mass spectrometry menu with antibiotics drug monitoring CE mark approval offering industry’s broadest in vitro diagnostic menu
F. Hoffmann-La Roche Ltd With this approval, Roche’s automated mass spectrometry platform now offers the industry’s broadest in vitro diagnostic menu with 39 tests, including tests for therapeutic drug monitoring for immunosuppressants an... Full story
Yahoo Finance • 2 months ago
Genentech’s Giredestrant Reduced Risk of Invasive Disease Recurrence or Death by 30% in ER-positive Early-Stage Breast Cancer
– Giredestrant is the only oral SERD to show superior invasive disease-free survival in the adjuvant setting, marking the first significant endocrine therapy advance in over 20 years – – Transformational results support the potential of g... Full story
Yahoo Finance • 2 months ago
Roche’s giredestrant reduced risk of invasive disease recurrence or death by 30% in ER-positive early-stage breast cancer
Giredestrant is the only oral SERD to show superior invasive disease-free survival in the adjuvant setting, marking the first significant endocrine therapy advance in over 20 years1-3Transformational results support the potential of girede... Full story
Yahoo Finance • 2 months ago
How New Lunsumio and Columvi Lymphoma Data At Roche (SWX:ROG) Has Changed Its Investment Story
In early December 2025, Roche and Genentech reported new clinical data at the American Society of Hematology meeting showing that Lunsumio and Columvi delivered promising efficacy, durable remissions and manageable safety profiles across m... Full story
